{
    "clinical_study": {
        "@rank": "35057", 
        "arm_group": {
            "arm_group_label": "triamcinolone acetonide (Triesence\u00ae)", 
            "arm_group_type": "Experimental", 
            "description": "TRIESENCE\u00ae (triamcinolone acetonide injectable suspension 40 mg/mL) in a total volume of 100 uL administered via microneedle directly to the suprachoroidal space (SCS)"
        }, 
        "brief_summary": {
            "textblock": "This study is designed to determine the safety and tolerability of a single microinjection\n      of triamcinolone acetonide (TRIESENCE\u00ae) into the suprachoroidal space (SCS) of patients who\n      have non-infectious uveitis."
        }, 
        "brief_title": "Safety Study of Suprachoroidal Triamcinolone Acetonide Via Microneedle to Treat Uveitis", 
        "condition": [
            "Uveitis", 
            "Intermediate Uveitis", 
            "Posterior Uveitis", 
            "Panuveitis", 
            "Noninfectious Uveitis"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Panuveitis", 
                "Uveitis", 
                "Chorioretinitis", 
                "Uveitis, Intermediate", 
                "Pars Planitis", 
                "Uveitis, Posterior"
            ]
        }, 
        "detailed_description": {
            "textblock": "This is a Phase 1/2, open-label study designed to evaluate the safety and tolerability of a\n      microneedle injection of triamcinolone acetonide (TA) into the SCS.  The subjects enrolled\n      in this study will be chosen from subjects with non-infectious intermediate, posterior and\n      pan-uveitis. The injection will only be administered to a single eye via the Clearside\n      Biomedical proprietary microneedle into the SCS.  The dose of TA to be injected is 4 mg of\n      currently approved TRIESENCE\u00ae (triamcinolone acetonide injectable suspension 40 mg/mL).  The\n      study design includes 10 clinic visits over 27 weeks.  Subjects will be followed for 26\n      weeks following treatment with TRIESENCE\u00ae."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  diagnosis of non-infectious intermediate, posterior or pan-uveitis\n\n        Exclusion Criteria:\n\n          -  any ocular trauma within the past 6 months in the study eye\n\n          -  any injection of intraocular corticosteroids or steroid implant or the Ozurdex\u00ae\n             implant in the 6 months prior to the study treatment, or any prior use of Retisert\u2122\n             in the study eye\n\n          -  any uncontrolled systemic disease that would preclude participation in the study or\n             put the subject at risk due to study treatment or procedures\n\n          -  have a known HIV infection or other immunodeficiency disease for which corticosteroid\n             therapy would be contraindicated\n\n          -  are monocular\n\n          -  have ocular hypertension\n\n          -  history of any intraocular surgery in the study eye\n\n          -  presence of an anterior staphyloma in the study eye"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "5", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 5, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01789320", 
            "org_study_id": "CLS1001-101"
        }, 
        "intervention": {
            "arm_group_label": "triamcinolone acetonide (Triesence\u00ae)", 
            "description": "4 mg of TRIESENCE\u00ae (triamcinolone acetonide injectable suspension 40 mg/mL) administered as a single injection to the suprachoroidal space", 
            "intervention_name": "triamcinolone acetonide (Triesence\u00ae)", 
            "intervention_type": "Drug", 
            "other_name": [
                "triamcinolone acetonide", 
                "TA", 
                "Triesence", 
                "corticosteroid"
            ]
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Triamcinolone hexacetonide", 
                "Triamcinolone", 
                "Triamcinolone Acetonide", 
                "Triamcinolone diacetate"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "uveitis", 
            "intermediate uveitis", 
            "posterior uveitis", 
            "panuveitis", 
            "noninfectious uveitis", 
            "microneedle", 
            "suprachoroidal space", 
            "SCS", 
            "inflammation", 
            "ocular inflammatory conditions", 
            "triamcinolone acetonide", 
            "TA", 
            "Triesence", 
            "injection", 
            "IVT", 
            "intravitreal", 
            "corticosteroid", 
            "sympathetic ophthalmia", 
            "temporal arteritis", 
            "vitreous haze"
        ], 
        "lastchanged_date": "August 13, 2013", 
        "location": [
            {
                "contact": {
                    "last_name": "Anna Castro-Malek", 
                    "phone": "312-695-0252"
                }, 
                "facility": {
                    "address": {
                        "city": "Chicago", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "60611"
                    }, 
                    "name": "Northwestern University"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "lisa.greer@UNMC.edu", 
                    "last_name": "Lisa Greer", 
                    "phone": "402-559-1851"
                }, 
                "facility": {
                    "address": {
                        "city": "Omaha", 
                        "country": "United States", 
                        "state": "Nebraska", 
                        "zip": "68198"
                    }, 
                    "name": "University of Nebraska Medical Center"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "BAYNESK@ccf.org", 
                    "last_name": "Kimberly Baynes", 
                    "phone": "216-444-2566"
                }, 
                "facility": {
                    "address": {
                        "city": "Cleveland", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "44195"
                    }, 
                    "name": "Cleveland Clinic Foundation"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Open-Label, Safety and Tolerability Study of Suprachoroidal Triamcinolone Acetonide Via Microneedle in Subjects With Non-Infectious Uveitis", 
        "overall_contact": {
            "email": "michelle.widmann@clearsidebio.com", 
            "last_name": "Michelle Widmann", 
            "phone": "678-270-3631"
        }, 
        "overall_contact_backup": {
            "email": "melanie.klotz@clearsidebio.com", 
            "last_name": "Melanie Klotz", 
            "phone": "678-270-3631"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "August 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Incidence of adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "Number of adverse events at 8 weeks"
            }, 
            {
                "measure": "Incidence of adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "Number of adverse events at 6 months"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01789320"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Central subfield thickness using optical coherence tomography (OCT)", 
                "safety_issue": "Yes", 
                "time_frame": "Change from baseline at 8 weeks and 26 weeks."
            }, 
            {
                "measure": "Vitreous haze grade", 
                "safety_issue": "Yes", 
                "time_frame": "Change from baseline at 8 weeks and 26 weeks"
            }, 
            {
                "measure": "Change in intraocular pressure (IOP)", 
                "safety_issue": "Yes", 
                "time_frame": "Change from baseline in IOP at 8 weeks"
            }
        ], 
        "source": "Clearside Biomedical, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Clearside Biomedical, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2013"
    }
}